RxDoctor Payments Data

Gregory Marra, MD

Family Medicine · Hamburg, NYNPI 1275997140

Payments from drug & device makers

$11,792in general payments, 2019–2025

Across 571 payments — averaging $20.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Pfizer$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AbbVie$896
  • GSK$830
  • plus $5K from 48 others

What the payments were for

  • Food & beverage$11,792100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,792 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$26,143
Medicare patients
112
Services billed
274

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$108,279
OzempicSemaglutide32$59,613
TrulicityDulaglutide50$52,621
XareltoRivaroxaban66$47,950
FarxigaDapagliflozin Propanediol32$41,056
MounjaroTirzepatide38$40,352
JardianceEmpagliflozin28$38,531
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$27,478
RybelsusSemaglutide15$20,588
LinzessLinaclotide22$19,928
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$13,433
SynjardyEmpagliflozin/Metformin Hcl15$11,250
Repatha SureclickEvolocumab13$8,110
SymbicortBudesonide/Formoterol Fumarate30$7,529
Rosuvastatin Calcium361$5,998

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,171$108,279108 claims
Lilly USA, LLCTrulicity, Mounjaro, Humalog$1,166$94,28999 claims
Novo NordiskOzempic, Rybelsus$1,127$80,20047 claims
Boehringer IngelheimJardiance, Synjardy$576$49,78143 claims
AstraZenecaFarxiga, Symbicort$1,482$48,58562 claims
Johnson & JohnsonXarelto$392$47,95066 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$830$36,87263 claims
AbbVieLinzess, Synthroid$896$20,95036 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$48$4,434251 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Hamburg

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →